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Intravenous itraconazole has been approved for second 
line therapy of invasive pulmonary aspergillosis. How- 
ever, little is known about its comparative antifungal 
efficacy against this disease in the state of persistent and 
profound neutropenia. We therefore investigated the 
pharmacokinetics and pharmacodynamics of intra- 
venous hydroxypropyl-beta-cyclodextrin itraconazole in 
a persistently neutropenic rabbit model of invasive 
pulmonary aspergillosis. 
Twenty-four hours following endotracheal inoculation 
with Aspergillus jumigatus, cohorts of 4 animals each 
received itraconazole at dosages ranging from 0.66 to 16 
mg/kg once daily as lo-minutes IV bolus for a total of 12 
days. Optimal plasma sampling was performed in each 
individual animal after the 5th dose to obtain pharma- 
cokinetic and pharmacodynamic parameters. Untreated 
animals and animals treated with standard amphotericin 
B deoxycholate (lmg/kg) served as controls. Responses 
to treatment were evaluated by survival and the residual 
fungal burden in lung tissue at autopsy. 
Intravenous itraconazole showed dose-dependent anti- 
fungal efficacy against invasive pulmonary aspergillosis. 
The relationship between dosage and residual fungal 
burden in lung tissue followed an inhibitory effect 
sigmoidal Emax function with an estimated ED50 of 7 
mg/kg. In comparison to untreated controls, treatment 
with dosages of 6.6 to 12 mg/kg resulted in a reduction 
of the residual fungal burden in lung tissue (p<O.OOOl) 
and improved survival (p ~0.001). Pharmacodynamic 
modeling revealed significant relationships between 
pharmacodynamic parameters, the residual fungal 
burden in lung tissue, and survival. Itraconazole was well 
tolerated without renal or hepatic laboratory abnor- 
malities. Acute dose-limiting neurological toxicity 
(seizures) occurred at 16mg/kg (2 animals). 
In conclusion, IV itraconazole displayed dose- 
dependent antifungal efficacy in a clinically relevant 
persistently neutropenic animal model of pulmonary 
aspergillosis. 
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Candida albicans is a polymorphic fungus that can 
switch between blastospores, pseudohyphae, and true 
hyphae. All three morphologic forms are frequently 
recovered from tissues of patients with disseminated 
candidiasis and are therefore important in the patho- 
genicity of C. albicans. Previously we cloned the 
Agglutinin-Like Sequence 1 (ALU) gene, which 
encodes a candidal cell surface protein. We demon- 
strated that Alsl protein (Alslp) is required for 
adherence to endothelial cells, and virulence in a mouse 
model of hematogenously disseminated candidiasis. 
To investigate the feasibility of using Alslp in vaccine 
strategies to protect against hematogenously dissemi- 
nated candidiasis, we studied the expression of ALSl in 
the three different morphologies of C. albicans. The 
expression of ALU was determined by Northern 
blotting, and confocal immunofluorescence microscopy 
using an ALSI specific probe and monoclonal antibody 
raised against the N-terminus of Alslp, respectively. 
RNA expression of ALSI was detected in all forms of 
C. albicans with maximal expression during lag phase of 
growth. Although Alslp was expressed during all 
polymorphic forms of C. albicans, localization of the 
protein on the cell surface was altered among these 
phases. Diffused staining was detected on the surface of 
blastospores. When cells were grown as pseudohyphae, 
Alslp expression was detected along the entire 
pseudohyphus. In contrast, in true hyphae, Alslp staining 
was most intense at the base of the emerging hyphae. 
The detection of Alslp expression on the cell surface 
during all three forms of C. albicans growth will prove 
to be beneficial in exploiting this protein to develop 
vaccine strategies against mucosal and disseminated 
candidiasis. 
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Introduction: Infections by filamentous fungi, parti- 
cularly Aspergillus spp., are increasing in incidence in 
immunocompromised patients and are associated with 
high morbidity and mortality. IL-15 is a Thl cytokine 
associated with the innate immune response, which has 
various enhancing effects on phagocytic function. IL-8 
is a potent chemokine and TNF-alpha has broad pro- 
inflammatory properties. We hypothesised that IL-15 
plays a role in modulation of the release of these two 
cytokines in response to Aspergillus spp. 
Methods: Polymorphonuclear leukocytes (PMNLs) 
were isolated by dextran sedimentation/ficoll centri- 
fugation from blood obtained from healthy adult donors. 
Following pre-treatment of PMNLs with or without 100 
rig/ml IL-15 for 22 hours, untreated and IL-15 treated 
PMNLs (1.5~ 10s/well) were incubated for 4 hours in 
HBSS, either unchallenged or challenged with hyphae of 
Aspergillus fumigatus, Aspergillus flavus or Verticillium 
nigrescens, a fungus of low pathogenicity, at E:T ratio 
